Zentalis Pharmaceuticals, Inc. (ZNTL) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Zentalis Pharmaceuticals Inc (ZNTL) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Zentalis is a small clinical-stage biotech betting almost everything on one lead cancer drug, so the stock can move a lot on trial updates because there isn’t a stable commercial business underneath yet. > **📍 Basic Profile** > > Market Cap **$0.19 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$5.56** > **⚡ 3 Things You Should Know** > > 1. 💊 Single-asset story: The recent excitement is mainly tied to azenosertib and its ovarian cancer trial update, which means upside can be huge if data stays strong—but concentration risk is also very high. > > 2. 💵 Balance sheet is better than income statement: Zentalis is deeply unprofitable today, but it has no debt and very strong liquidity ratios, so the immediate issue is not solvency—it’s whether cash lasts long enough to get meaningful clinical proof. > > 3. 🎢 Market is trading the narrative, not earnings: The stock is near its 52-week high after analyst target hikes and trial-related optimism, even though there is no PE ratio and cash flow remains negative, so buyers are paying for future success rather than current fundamentals. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | ROE -52.8%, negative cash flow, no commercial earnings base | > | Growth Rate | [Data unavailable] | Revenue growth data unavailable; clinical progress matters more than sales today | > | Financial Health | Healthy💚 | Debt ratio 0%, current ratio 6.93 | > | Valuation | Pricey | No PE; stock sits ~77% up its 52-week range near the high | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Zentalis develops oncology drug candidates for cancer patients, and for now it mainly uses investor capital to fund R&D rather than generating meaningful product sales. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Drug development / pipeline programs | [Data unavailable] | → | Clinical-stage biotech; value comes from pipeline progress rather than current revenue | | Commercial product revenue | [Data unavailable] | → | No meaningful commercial revenue disclosed in the provided data | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | [Data unavailable] | [Data unavailable] | Not very useful here because this is not a mature revenue-generating biotech | | Net Margin | [Data unavailable] | [Data unavailable] | Loss-making profile is expected for a clinical-stage company | | ROE | -52.77% | Below Average | Basically, shareholders’ capital is being consumed to fund trials rather than producing returns today | --- #### 📈 How's the Growth? **Growth Assessment:** [Data unavailable] / Pipeline-driven | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | Losses appear narrower on recent quarterly EPS, but full profit trend data is limited | **Growth Quality:** > What’s interesting is that “growth” for Zentalis should really be read as clinical de-risking, not revenue expansion. Recent interim trial data supporting the 400mg monotherapy dose of azenosertib is the kind of update that can create value more meaningfully than near-term sales growth, but it also means sentiment can reverse quickly if later-stage data disappoints. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a startup with a big cash cushion and no debt, but no paycheck yet—it can operate for now, though it still burns cash while waiting for its big product bet to work. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% | <60% safe | ✅Safe | | Current Ratio | 6.93 | >1.5 healthy | ✅Safe | | Cash Flow | Negative (cash flow/share -3.33) | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $1.01 - 52-Week High: $6.95 - Current: $5.56, **very close to high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(76.6% position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE [Data unavailable] | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > In other words, the market is betting that azenosertib keeps producing encouraging data and moves closer to becoming a real oncology asset with commercial value. With no earnings-based valuation anchor, the stock price mostly reflects probability-weighted expectations for future trial success, partnership potential, or eventual approval. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-09 | Guggenheim maintained Buy and raised price target from $6 to $10 | Positive — shows improving external confidence after recent data, and helped fuel momentum | | 2026-04-08 | Zentalis selected 400mg as optimal monotherapy dose of azenosertib in DENALI Part 2a | Positive — important clinical execution signal for the lead program | | 2026-03-25 | Q4 EPS headline indicated a miss versus estimate | Negative — reminds you this is still a cash-burning development-stage biotech, not an earnings story | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -52.77% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $(0.59) | $(0.50) | +15.3% Beat 😀 | | 2025-09-30 | $(0.54) | $(0.37) | +31.3% Beat 😀 | | 2025-06-30 | $(0.59) | $(0.37) | +37.6% Beat 😀 | | 2025-03-31 | $(0.65) | $(0.56) | +13.9% Beat 😀 | **Earnings Trend Interpretation:** Recent quarterly results have consistently beaten lowered expectations, which is better than repeated misses, but for a biotech like this, EPS beats matter less than trial progress and cash runway. Basically, the market will forgive accounting losses if the lead drug keeps getting de-risked. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 9 firms | 60.0% | | Hold | 6 firms | 40.0% | | Sell | 0 firms | 0.0% | **Target Price:** $10 ~ $10 (Median $10) **vs Current Price:** **~79.9% upside** **Insider Activity:** Net **selling** about **55,372 shares** in the past 3 months based on the transactions provided > Worth noting, insider selling in biotech is not automatically bearish because it can reflect tax withholding or compensation-related sales. Still, when there’s no insider buying to offset it, it doesn’t give you an extra confidence signal either. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Clinical risk:** Zentalis is heavily tied to azenosertib and related trial outcomes → If later data disappoints, the stock could reprice very sharply. 2. **Cash burn risk:** Cash flow remains negative despite strong liquidity ratios today → If development timelines stretch, future dilution could become necessary. 3. **Volatility risk:** Beta is 2.13 and the stock just fell nearly 16% in one session despite recent positive headlines → If sentiment turns risk-off, price swings can be brutal even without fundamental news. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Zentalis is a clinical-stage oncology biotech whose value is mainly tied to whether azenosertib becomes a real winner. > > **Key strength:** The company has a clean balance sheet, strong liquidity, and a recent clinical update that gave the market a reason to re-rate the stock. > > **Key risk:** There’s no durable earnings base here, so if trial progress stalls or cash burn drags on too long, the shares could fall hard. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis